Clinical trial
SCH-58235 (Ezetimibe) to Treat Homozygous Sitosterolemia
NCT00045812 · National Heart, Lung, and Blood Institute (NHLBI), NIH · Completed
Key facts
| NCT number | NCT00045812 |
|---|---|
| Title | SCH-58235 (Ezetimibe) to Treat Homozygous Sitosterolemia |
| Official title | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate SCH-58235 in Homozygous Sitosterolemia |
| Lead sponsor | National Heart, Lung, and Blood Institute (NHLBI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lipoidosis |
| Intervention type | Drug |
| Interventions | SCH-58235 |
| Enrollment | 5 |
| Start date | Mar 1, 2001 |
| Completion | Apr 1, 2004 |
| First posted | Sep 11, 2002 |
| Last update posted | Mar 4, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: